Receive up to €500,000 in CDMO services to accelerate your oncology biologic.
Mabion is awarding up to €500,000 in development services to support the advancement of one outstanding oncology-focused biologic — whether a novel therapeutic or a biosimilar aimed at expanding access to lifesaving oncology care.
The winning candidate will be selected by a panel of leading experts in oncology research and biomanufacturing, based on scientific merit, clinical potential and feasibility.
Apply by 30 September 2025
Biotech breakthroughs shouldn’t be delayed by funding gaps or infrastructure limits
Many lifesaving biopharmaceuticals are suffering from a slump in venture funding. Novel recombinant protein based therapeutics, but also biosimilars are needed to fill the gaps in unmet patient needs.
At Mabion, we know how hard it is to take an oncology biologic from concept to clinic, because we’ve done it ourselves. In today’s constrained funding environment, too many promising oncology candidates are stalling before they reach the clinic, not because the science isn’t there, but because the infrastructure and resources aren’t.
That is why we are launching the “Unlocking the Future of Therapeutics” competition, with the ultimate goal of helping a deserving biotech team reach their next milestone faster and bring new hope to patients.
The winner will receive:
€500,000 in credit toward Mabion’s biologics CDMO services
End-to-end support including:
CMC development
Analytical and QC services
GMP drug substance or product manufacturing
Regulatory and project management guidance
NDA and proposal support for continued development
Visibility through press coverage and live announcement at CPHI Frankfurt
“Nothing in life is to be feared; it is only to be understood.“
Marie Skłodowska-Curie
Let’s grow together!
Apply Now
The deadline is 30 September 2025 at 23:59 CET.
Applications will be reviewed in October, and the winner will be announced live at CPHI Frankfurt.
Submit your therapeutic for consideration today and take the next step toward clinical development, with the right partner by your side.
Entry Form
The upper limit on the total size of an attached file to an e-mail message is 50 MB. Don’t worry, our BD specialists will take care of you. With larger files, send them straight to bd@mabion.eu
Principal Investigator at Sanquin and Professor of Immunoglobulin Biotherapeutics at the Utrecht Institute for Pharmaceutical Sciences
Gestur Viðarsson, Prof.
Principal Investigator at Sanquin and Professor of Immunoglobulin Biotherapeutics at the Utrecht Institute for Pharmaceutical Sciences
Leading international expert in immunoglobulin-based biotherapeutics. His main research interests are antibody engineering, molecular biology and immunology. His goal is to understand antibody mediated functions in the broadest term.
Tadeusz Pietrucha, Prof.
Head of the Medical Biotechnology Department at Medical University of Łódź
Tadeusz Pietrucha, Prof.
Head of the Medical Biotechnology Department at Medical University of Łódź
Polish biotechnologist and molecular biologist, founder of the Polish Biotechnology Society, Bio-Forum Łódź and godfather of several Polish biotechnology companies, member of the General Council for Higher Education, Science and Innovation to the President of Poland.
Alicja Santos, PhD
Chief Executive Officer of Polonium Foundation
Alicja Santos, PhD
Chief Executive Officer of Polonium Foundation
Accomplished healthcare innovation leader with nearly two decades of product developemnt and strategy advisory experience spanning cancer, cardiomyopathies and infectious diseases research. Operating on the interface of science, entrepreneurship and business; practicing compassionate leadership across academic, startup, VCs and Fortune 500 environments.
Julita Balcerek,
PhD, MBA, IPMA C
Chief Operating Officer of Mabion
Julita Balcerek,
PhD, MBA, IPMA C
Chief Operating Officer of Mabion
In charge of coordinating the Company’s development, manufacturing, investment, and maintenance as well as qualification efforts. Responsible for creation and implementation of new process technologies and development of analytics characterizing biological products and processes. Oversees activities related to purchasing, warehousing, transportation and investment processes.
FAQ
Mabion launched this contest to support promising oncology innovations that struggle to progress due to limited funding. With a history in drug development, Mabion seeks to help advance impactful therapies and promote Polish scientific excellence in medical research.
No. This is a competitive award. Up to the €500,000 in services will be awarded to one outstanding oncology therapeutic, selected by an expert panel.
Programs in preclinical to early clinical development are ideal. You should have a defined development plan and a need for CDMO support.
Yes. This is a global opportunity. The only requirement is that your therapeutic aligns with the oncology focus and development stage.
No. There’s no obligation to continue working with Mabion after the funded support, but we’d love to be your partner long-term.
The oncology pipeline is growing rapidly, yet funding remains a major barrier, especially for biologics. Mabion sees this as a critical moment to close that gap and accelerate novel therapies to patients.
Mabion offers end-to-end biologics development and manufacturing under one roof, reducing risks and speeding timelines. Operating from a cost-effective EU base, Mabion combines regulatory excellence, personalized project management, and integrated quality systems.
The winner receives €500,000 in service credits for biologics development, plus support with NDAs, proposal structuring, and business development. Mabion acts as a true partner, helping accelerate the project toward clinical readiness.
You do. Mabion will operate under strict confidentiality agreements and does not claim ownership of your therapeutic program.
The jury includes experts from academia and industry, chosen for their scientific and translational experience. They assess proposals based on impact, feasibility, and clinical potential, ensuring patient relevance and real-world viability.
Mabion aims to be a strategic CDMO partner by investing in high-potential biotech programs. This contest supports that goal by strengthening its oncology focus and building long-term collaborations.
Mabion hopes to speed up the development of new cancer treatments by equipping innovators with critical infrastructure. For biotech, it shows how CDMOs can drive innovation; for patients, it offers hope for faster access to breakthrough therapies.
“Further is closer. The breakthrough you need is closer than you think.“
Nigel Stapleton VP of Business Development – Head of Europe at Mabion
